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Abstract
Recent evidence has unveiled a subpopulation of highly tumorigenic, multipotent cells capable of self-renewal in
head and neck squamous cell carcinomas (HNSCCs). These unique cells, named here cancer stem cells (CSCs),
proliferate slowly and might be involved in resistance to conventional chemotherapy. We have shown that CSCs
are found in perivascular niches and rely on endothelial cell–secreted factors [particularly interleukin-6 (IL-6)] for
their survival and self-renewal in HNSCC. Here, we hypothesized that cisplatin enhances the stem cell fraction
in HNSCC. To address this hypothesis, we generated xenograft HNSCC tumors with University of Michigan–
squamous cell carcinoma 22B (UM-SCC-22B) cells and observed that cisplatin treatment increased (P = .0013) the
fraction of CSCs [i.e., aldehyde dehydrogenase activity high and cluster of differentiation 44 high (ALDHhighCD44high)].
Cisplatin promoted self-renewal and survival of CSCs in vitro, as seen by an increase in the number of orospheres
in ultralow attachment plates and induction in B lymphoma Mo-MLV insertion region 1 homolog (Bmi-1) and
octamer-binding transcription factor 4 expression. Cisplatin-resistant cells expressed more Bmi-1 than cisplatin-
sensitive cells. IL-6 potentiated cisplatin-induced orosphere formation generated when primary human HNSCC cells
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were sorted for ALDHhighCD44high immediately after surgery and plated onto ultralow attachment plates. IL-6–
induced signal transducer and activator of transcription 3 (STAT3) phosphorylation (indicative of stemness) was
unaffected by treatment with cisplatin in UM-SCC-22B cells, whereas IL-6–induced extracellular signal–regulated
kinase (ERK) phosphorylation (indicative of differentiation processes) was partially inhibited by cisplatin. Notably,
cisplatin-induced Bmi-1 was inhibited by interleukin-6 receptor blockade in parental and cisplatin-resistant cells.
Taken together, these results demonstrate that cisplatin enhances the fraction of CSCs and suggest a mechanism
for resistance to cisplatin therapy in head and neck cancer.
Neoplasia (2014) 16, 137–146
Introduction
Drug resistance is a critical problem in cancer treatment. Head and
neck squamous cell carcinoma (HNSCC), one of the most common
types of cancer afflicting more than half a million people worldwide
each year, exhibits an unacceptably poor patient survival [1,2]. The
standard of care for head and neck tumors used to be surgery and
radiation. The addition of platinum-based drugs led to an improve-
ment in local disease control and organ preservation [3]. However,
the overall survival of patients with HNSCC has not changed sig-
nificantly for the last three decades. This has been attributed to
the development of chemoresistance and incidence of distant metas-
tasis [4–6]. Understanding the mechanisms underlying resistance to
chemotherapy might have a profound impact in the survival of patients
with head and neck cancer.
This clinical scenario suggests that some tumor cells are unaffected
by chemotherapy and have the capability to migrate and initiate a new
tumor. Considering that tumors are complex “organs” constituted by
many subtypes of tumor cells, it is plausible that resistance to therapy
is related to a subpopulation of less differentiated, multipotent, and
self-renewing cells, named cancer stem cells (CSCs), that are uniquely
resistant to therapy [7,8]. Such CSC cells are capable of initiating
tumors and disseminate from the primary tumor to promote metas-
tasis [9–11]. Notably, current therapies targeted to highly prolifera-
tive cells can affect tumor bulk by killing differentiated tumor cells
but may spare the CSCs that are believed to exhibit slow proliferation
rates. Indeed, it has been recently shown that stem cells survive anti-
cancer treatment in some tumor types, as for example lung cancer
[12], glioblastoma [13], and breast cancer [11]. These findings are
aligned with the concept that CSCs are key mediators of resistance
to therapy leading to recurrence or metastasis [14]. Head and neck
tumors contain a small and highly tumorigenic subpopulation of cells
with stem and self-renewal properties [15,16]. It is possible that ther-
apies targeting CSCs, used in combination with conventional “tumor
debulking” agents, may become a more efficient strategy in the treat-
ment of patients with head and neck cancer.
The goal of targeting CSC has remained elusive. CSC shares many
characteristics with normal stem cells, which makes specific targeting
very difficult. In addition, CSC exhibits high drug efflux through
ATP-binding cassette transporters [17]. Indeed, this feature has been
used to identify stem cells [18,19]. Because the direct target of CSC
seems to be difficult, other approaches have been considered, as for
example to target supportive cells of the CSC niche. It has been
found that CSC depends on the tumor microenvironment for their
growth and survival and proposed that therapeutic targeting of the
supportive niche might result in ablation of CSC [20,21]. We have
shown that head and neck CSCs reside in perivascular niches and
that their cross talk with vascular endothelial cells is critical for
their survival and self-renewal [16]. This suggests that the blockade
of the cross talk between endothelial cells and CSC might sensitize
these cells to conventional chemotherapy. We have previously reported
that interleukin-6 (IL-6) expression is upregulated in endothelial cells
cocultured with HNSCC cells and that blockade of endothelial cell–
derived IL-6 inhibits signal transducer and activator of transcription
3 (STAT3) signaling and survival and migration of unsorted HNSCC
cells [22]. IL-6 signaling through IL-6 receptor (IL-6R) and activation
of the Janus kinase (JAK)/STAT3 pathway have been implicated in the
tumorigenic behavior of CSC, at least in breast cancer models
[11,23,24]. We have also observed that IL-6 expression is higher
in vascular endothelial cells than in tumor cells in human HNSCC
and that IL-6R expression is higher in the CSC than in the non-CSC
in these tumors. Notably, there is a strong correlation between in-
creased pretreatment serum IL-6 levels and poor survival of patients
with HNSCC [25]. Here, we tested the hypothesis that cisplatin
enhances the fraction of CSCs in head and neck cancer.
Materials and Methods
Cell Culture
Cells derived from primary human HNSCC tumors were prepared
within 12 hours after surgery. Tumors were cut into small pieces,
minced with a sterile scalpel, resuspended in a mix of 9:1 Dulbecco’s
modified Eagle’s medium–F12 (DMEM-F12; Hyclone, Waltham,
MA) and collagenase/hyaluronidase (STEMCELL Technologies,
Vancouver, British Columbia), and incubated for 1 hour at 37°C.
The mixture was filtered through a 40-μm nylon mesh (BD Falcon,
Franklin Lakes, NJ) and resuspended in low-glucose DMEM, as we
described [16]. The primary tumors were obtained from patients on
signature of informed consent under an approved Institutional
Review Board (IRB) protocol. HNSCC cell lines [University of
Michigan–squamous cell carcinoma 1 (UM-SCC-1), UM-SCC-22A, and
UM-SCC-22B; gift from Dr Carey, University of Michigan, Ann
Arbor, MI) were cultured in DMEM (Invitrogen, Grand Island,
NY), 10% FBS (Invitrogen), and 100 U/ml penicillin-streptomycin
(Invitrogen). The identity of all tumor cell lines was confirmed by
genotyping.Human dermalmicrovascular endothelial cells (HDMECs;
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Lonza, Walkersville, MD) were cultured in endothelial cell growth me-
dium 2 (EGM-2MV; Lonza).
Severe Combined Immunodeficient Mouse Model of
Human Tumor Angiogenesis
Xenograft HNSCC tumors with humanized vasculature were
generated in severe combined immunodeficient (SCID) mice (CB17
SCID; Taconic, Germantown, NY) as we described [26]. Briefly,
1 × 105 tumor cells (UM-SCC-22B)were seededwith 9 × 105HDMEC
in poly-(L-lactic) acid (Medisorb, Nicosia, Cyprus) biodegradable
scaffolds. Mice were anesthetized with ketamine (Hospira, Inc; Lake
Forest, IL)/xylazine (Lloyd Laboratories; Shenandoah, IA), and
bilateral scaffolds were implanted subcutaneously in the dorsum of
each mouse (n = 12). Mice were monitored daily for tumor growth,
and treatment (weekly intraperitoneal injection, 5 mg/kg cisplatin
(Bedford Laboratories; Bedford, OH) or vehicle) started when the
average volume of the tumors reached 200 mm3 (n = 12 tumors
per experimental condition). At termination of the experiment,
mice were killed, and tumors were retrieved, measured, weighed,
and processed for histology and flow cytometry. The care and treat-
ment of experimental animals were in accordance with University of
Michigan institutional guidelines.
Immunohistochemistry
Paraffin-embedded tissues were treated with peroxidase (Dako,
Carpinteria, CA) and submitted to antigen retrieval for 30 minutes at
95°C. Tissues were exposed to 1:100 dilution of the anti–B lymphoma
Mo-MLV insertion region 1 homolog (anti–Bmi-1; Abcam,Cambridge,
United Kingdom) or 1:50 of the anti-cluster of differentiation 44
(CD44; Cell Signaling Technology, Danvers, MA) overnight at 4°C.
Flow Cytometry
Single-cell suspensions were obtained either from trypsinization of
cell lines or digestion of tumor specimens from patients. ALDEFLUOR
kit (STEMCELL Technologies) was used to identify cells with high
aldehyde dehydrogenase (ALDH) activity, as previously reported [16].
Cells were suspended with activated ALDEFLUOR substrate amino-
acetaldehyde (BAAA) or the ALDH inhibitor diethylaminobenzal-
dehyde (DEAB) for 45 minutes at 37°C. Then, cells were exposed to
anti-CD44 antibody (clone G44-26BD; BD Pharmingen, Franklin
Lakes, NJ) and lineage markers (i.e., anti-CD2, anti-CD3, anti-
CD10, anti-CD16, and anti-CD18; BD Pharmingen) preconjugated
with phycoerythrin-cyanine dye 5 (PE-cy5).Mouse cells were identified
using anti-H2K antibody (BD Biosciences, Franklin Lakes, NJ) and
eliminated. 7-Aminoactinomycin (BD Pharmingen) was used to select
live cells.
Cytotoxicity Assay
Sulforhodamine B (SRB) cytotoxicity assay was performed, as we
described [27]. Briefly, cells were seeded at 2 × 103 cells per well in
96-well plates, allowed to attach overnight, and treated with cisplatin
for 48 to 96 hours. Cells were fixed with 10% TCA and stained with
0.4% SRB (Sigma-Aldrich, St Louis, MO) in 1% acetic acid, and
plates were read in a microplate reader at 560 nm (GENios; Tecan,
Männedorf, Switzerland). Data were obtained from triplicate wells
per condition and represent three independent experiments.
Orospheres
Orospheres, i.e., nonadherent spheroids of ≥25 cells, were gen-
erated by seeding one cell per well in one ultralow attachment plate
per experimental condition (Corning, Corning, NY), as we showed
[28]. Cells were plated immediately after sorting and treated with
0, 0.02, 0.2, or 2 μM cisplatin with or without recombinant human
IL-6 (rhIL-6; R&D Systems, Minneapolis, MN) for 10 days when
the spheres were counted under microscope.
Western Blot Analysis
UM-SCC-1, UM-SCC-22A, and UM-SCC-22B cell lines were
plated, serum starved overnight, and treated with cisplatin at the
indicated concentrations, 0 to 20 ng/ml rhIL-6 and 0 to 10 μg/ml
anti–IL-6 neutralizing antibody (R&D Systems) or 0 to 10 μg/ml
anti–IL-6R antibody (tocilizumab; Genentech, San Francisco, CA),
and Western blot analyses were performed. Primary antibodies were
as follows: mouse anti-human phospho-STAT3, rabbit anti-human
STAT3, rabbit anti-human phospho-extracellular signal–regulated
kinase (ERK)1/2, mouse anti-human ERK1/2, rabbit anti-human
phospho-AKT, rabbit anti-human AKT, rabbit anti-human Bmi-1, mouse
anti-human CD44 (Cell Signaling Technology), and mouse anti–
glyceraldehyde-3-phosphate dehydrogenase (Chemicon/Millipore,
Billerica, MA). Immunoreactive proteins were visualized by Super-
Signal West Pico Chemiluminescent Substrate (Thermo Scientific,
Rockford, IL).
Cisplatin-Resistant HNSCC Cell Lines
Cisplatin-resistant derivative cell lines were generated from UM-
SCC-22B cells, as described [29]. Briefly, the parent cell line was
submitted to repeated subcultures in the presence of increasing con-
centrations of cisplatin from 0.5 to 12 μM during a 3-month period.
Each concentration was applied twice, and exposure was continuous
for more than 3 days. Four cisplatin-resistant cell lines were generated
as follows: UM-SCC-22BCis1 (UM-SCC-22B resistant to 1 μM cis-
platin), UM-SCC-22BCis4 (UM-SCC-22B resistant to 4 μM cis-
platin), UM-SCC-22BCis6 (UM-SCC-22B resistant to 6 μM cisplatin),
and UM-SCC-22BCis12 (UM-SCC-22B resistant to 12 μMcisplatin).
Statistical Analysis
One-way analysis of variance and t test were performed using the
SigmaStat 3.1 software (SPSS, Chicago, IL). Statistical significance was
determined at P < .05.
Results
Cisplatin Enhances the Fraction of CSCs in HNSCC
To evaluate the effect of cisplatin on the head and neck CSC frac-
tion, we generated HNSCC xenografts with humanized vasculature,
as shown [16,26]. When tumors reached 200 mm3, we began weekly
injections with 5 mg/kg cisplatin for 2 weeks and killed the mice on the
day after the last dose (Figure 1A). This treatment regimen did not
cause a significant decrease in tumor volume (data not shown). Quali-
tative immunohistochemical analysis showed strong staining for Bmi-1
and CD44 in tumors retrieved from cisplatin-treated mice (Figure 1B).
Importantly, we observed a significant increase in the fraction of
CSCs identified as double staining [i.e., aldehyde dehydrogenase activ-
ity high and cluster of differentiation 44 high (ALDHhighCD44high)] in
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mice treated with cisplatin, when compared with vehicle control mice
(Figure 1C). To begin to understand possible mechanisms underlying
these results, we performed SRB assays that showed the expected
dose-dependent cytotoxicity of cisplatin at 48 and 72 hours, using two
well-established HNSCC cell lines (UM-SCC-1 and UM-SCC-22B)
from the Carey laboratory (Figure 1, D and E ). We determined
that the half maximal inhibitory concentration (IC50) for unsorted
UM-SCC-1 was 2.305 μM cisplatin and for UM-SCC-22B was
2.400 μM cisplatin at 72 hours (Figure W1). Knowing that high
IL-6 expression in serum correlates with poor survival of patients
with HNSCC [25] and that IL-6 is important for the survival and
stemness of CSCs in breast cancer [23], we interrogated the effect of
Figure 1. Cisplatin enhances the fraction of CSCs in HNSCC. (A) Schematic drawing depicts the experimental design. Xenograft tumors
were generated by the transplantation of human HNSCC cells (UM-SCC-22B) and primary human endothelial cells (HDMEC) in SCID
mice. When tumors reached an average size of 200 mm3, mice began to receive weekly intraperitoneal injections (5 mg/kg cisplatin
or vehicle). (B) Photomicrographs of histologic sections immunostained for CD44 and Bmi-1 from xenograft tumors treated with cisplatin
or vehicle controls. (C) Graph depicts the fraction of CSCs (as defined by ALDHhighCD44high) in xenograft tumors treated with cisplatin or
vehicle control (n = 11). Asterisk depicts P = .0013. (D and E) Graphs depict the viability of UM-SCC-22B (D) and UM-SCC-1 (E) cells, as
determined by the SRB assay. Cells were preincubated for 1 hour with 20 ng/ml rhIL-6 and then coincubated with cisplatin (0-20 μM) and
rhIL-6 for 24 to 72 hours. (F and G) Flow cytometric analysis of ALDH/CD44 status of UM-SCC-22B cells treated with rhIL-6 and/or cisplatin.
Cells were preincubated for 1 hour with rhIL-6 and then coincubated with cisplatin (0 or 2 μM) and rhIL-6 (0-50 ng/ml) for 24 hours.
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IL-6 on cisplatin-induced death of unsorted HNSCC cells. We
observed that IL-6 did not protect unsorted HNSCC cells against
cisplatin-mediated cell death (Figure 1, D and E ). In contrast,
single-agent cisplatin enhanced the fraction of CSCs in vitro, as
determined by FACS analysis for ALDH activity and CD44 expres-
sion (Figure 1, F and G ). Furthermore, when both cisplatin and
IL-6 were combined, we observed a dose-dependent increase (for
IL-6) in the fraction of ALDHhighCD44high cells (Figure 1G ). Col-
lectively, these data demonstrate that the combination of cisplatin
treatment with the high expression of IL-6, which is typically ob-
served in HNSCC [30], leads to a dramatic increase in the fraction
of CSCs.
Cisplatin Enhances the Stemness of Primary Human Head
and Neck CSCs
To evaluate the effect of cisplatin on the stemness of humanHNSCC
cells, we obtained specimens immediately after surgery and sorted
these cells for ALDH activity and CD44 expression. The average
fraction of ALDHhighCD44high in these primary human tumors was
3.2 +/− 2.6% (Figure W2). Single ALDHhighCD44high cells were
plated onto ultralow attachment 96-well plates and observed for
10 days as shown [28]. Qualitative assessment showed a trend for
larger orospheres in the wells treated with cisplatin and IL-6, when
compared with controls (Figure 2A). Notably, we observed a dose-
dependent increase in the number of orospheres when primary human
CSCs were treated with cisplatin and IL-6 together (Figure 2B).
Notably, the highest dose of cisplatin (20 μM) was very cytotoxic to
the cells cultured in ultralow attachment plates, killing most (if not
all) cells (data not shown).
To begin to understand possible mechanisms involved in this
increase in the number of orospheres, we exposed a pair of HNSCC
cell lines (UM-SCC-22A and UM-SCC-22B) to increasing concen-
trations of cisplatin in the presence/absence of IL-6. We observed
that cisplatin by itself mediated a dose-dependent increase in the
expression of Bmi-1 (Figure 2C ), a member of the polycomb group
family of transcriptional regulators that plays an essential role in stem
cell fate decisions and regulates the self-renewal capacity of normal
and CSCs [31,32]. Notably, combined use of cisplatin and IL-6
further enhanced expression of Bmi-1 in these cells (for concen-
trations up to 0.2 μM cisplatin), when compared to single-agent cis-
platin (Figure 2C ). We observed a trend for increasing expression of
CD44 with increasing concentrations of cisplatin and further poten-
tiation by combination of cisplatin and IL-6 (Figure 2D). To validate
these results using an alternative approach, we used a third cell line
(UM-SCC-1) and observed that either IL-6 or cisplatin induces
strong expression of Bmi-1 and that treatment with IL-6 or cisplatin
induced expression of the stem cell marker CD44 (Figure W3).
Effect of Cisplatin on Key Signaling Pathways Involved in the
Regulation of Stemness
STAT3 is the prototypic downstream signaling molecule for IL-6
and is constitutively activated in several malignancies including head
Figure 2. Cisplatin and IL-6 enhance Bmi-1 and the stemness of HNSCC cells. (A and B) Primary human HNSCC cells were sorted for
ALDH and CD44 immediately after surgery. ALDHhighCD44high cells were cultured in ultralow attachment plates for 10 days. (A) Photo-
micrographs depict orospheres (nonadherent spheres of >25 HNSCC cells) after treatment with cisplatin (0-2 μM) and/or rhIL-6 (20 ng/ml)
or vehicle control. (B) Graph depicts the number of orospheres generated with primary human HNSCC cells treated with cisplatin (0-2 μM)
and/or rhIL-6 (0 or 20 ng/ml). Asterisk depicts P < .05. (C) Western blot analysis depicts the expression of Bmi-1 in UM-SCC-22A and
UM-SCC-22B cells treated with cisplatin (0-2 μM) and/or rhIL-6 (0 or 20 ng/ml) for 24 hours. (D) Western blot analysis depicts the expression
of CD44 in UM-SCC-22A and UM-SCC-22B cells treated with cisplatin (0-2 μM) and/or rhIL-6 (0 or 20 ng/ml) for 24 hours.
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and neck cancer [33,34]. It is known that the activation of the
STAT3 signaling pathway is critical for the maintenance of the
stemness of mammary and brain CSCs [23,24,35,36]. Here, we first
confirmed that, indeed, IL-6 specifically activated STAT3 signaling,
as well as the critical prosurvival AKT and ERK pathways
(Figure 3A). We observed that IL-6–induced STAT3 phosphory-
lation was not affected by cisplatin (Figure 3B) in the cell line that
was used for the in vivo experiment shown in Figure 1 (UM-SCC-
22B), even when a high concentration of cisplatin (i.e., 5 μM) was
used (Figure 3C ). Interestingly, in UM-SCC-1, the phosphorylation
of STAT3 was inhibited at the highest concentrations of cisplatin
(Figure 3C ). In contrast, we observed a dose-dependent partial inhi-
bition of AKT and ERK phosphorylation with increasing concentra-
tions of cisplatin in both cell lines (Figure 3C ). Interestingly, ERK
phosphorylation has been observed in cells undergoing differentia-
tion [37]. Furthermore, we observed that cisplatin mediated a dose-
dependent inhibition of the expression of cyclin-dependent kinase 4
(CDK4; Figure 3D), a Ser/Thr protein kinase that is important for
G1 cell cycle progression [38]. Together, these data suggest that IL-6
enhances the stemness of HNSCC cells and that cisplatin cannot over-
come IL-6–induced signaling pathways that are involved in the acqui-
sition of a stemlike phenotype in UM-SCC-22B cells.
Cisplatin-Resistant Cells Are Endowed with
Cancer Stemlike Features
To further investigate the effect of cisplatin on stemness inHNSCC, we
generated cisplatin-resistant cell lines by exposing HNSCC to increasing
concentrations of this drug (Figure 4A). TheUM-SCC-22BCis1 is resistant
to 1 μM cisplatin, UM-SCC-22BCis4 is resistant to 4 μM, and so forth.
We observed that UM-SCC-22BCis12 form more orospheres when cul-
tured in ultralow attachment plates, when compared to the parental UM-
SCC-22B (Figure 4B). Cisplatin alone increases orosphere number in the
parental cell line (Figure 4B). We also observed that, in the UM-SCC-
22BCis12 cells, either IL-6 or cisplatin does not induce further the number
of orospheres (Figure 4B). Notably, unstimulated cisplatin-resistant
HNSCC cells express higher levels of Bmi-1 and octamer-binding tran-
scription factor 4 (Oct-4), two markers of stemness (Figure 4, C–E).
To further examine the effect of cisplatin resistance on response to
IL-6, we exposed cisplatin-resistant cells to this cytokine and observed
that it did not induce Bmi-1 or Oct-4 expression beyond what was
observed in the parental cells (Figure 4, D and E ). Surprisingly, we
observed that 2 μM cisplatin had a somewhat inhibitory effect on
Bmi-1 andOct-4 expression in the UM-SCC-22BCis12 cells (Figure 4,
D and E ). IL-6 potently activated STAT3 phosphorylation in both
parental cells and cisplatin-resistant cells (Figure 5A). Interestingly,
Figure 3. Effect of cisplatin on key signaling pathways involved in the regulation of stemness. HNSCC cells were serum starved over-
night and then treated with cisplatin (0-5 μM), rhIL-6 (0-50 ng/ml), and/or anti–IL-6 neutralizing antibody (0-10 μg/ml) for 30 minutes. (A–C)
Western blot analysis for phosphorylated and total STAT3, ERK, and AKT in UM-SCC-22B and UM-SCC-1 cells. (D) Western blot analysis
for CDK4 in UM-SCC-22B and UM-SCC-1 cells.
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the most resistant cells (i.e., UM-SCC-22BCis12) were the ones
that expressed the lower levels of the differentiation signaling mol-
ecule p-ERK (Figure 5A). These findings cannot be attributed to
differential levels of IL-6R expression levels in both parental cells
and cisplatin-resistant cells, treated and untreated (Figure 5B).
Blockade of IL-6R signaling with the Food and Drug Administration
(FDA)-approved humanized anti–IL-6R antibody tocilizumab partially
inhibited Bmi-1 expression in parental cells and in cells resistant to cis-
platin (Figure 5C ). Interestingly, the same effect was not observed
when we used an anti–IL-6 antibody (Figure 5C ). Collectively, these
data demonstrate that cisplatin-treated and cisplatin-resistant cells
exhibit enhanced stemness and suggest that therapeutic IL-6R blockade
might overcome this effect by downregulating Bmi-1 expression.
Discussion
Cisplatin is the most frequently used chemotherapeutic drug for
the treatment of HNSCC [39]. When combined with radiotherapy,
cisplatin improves organ preservation and enhances the quality of
life of patients with head and neck cancer [40]. However, the overall
survival of patients with head and neck cancer has not improved
significantly for the last 30 years [2], despite the extensive use of
platinum-based therapies for the last two decades. This appears to be
related to the observation that some tumor cells exhibit resistance to
cisplatin and are able to regrow and regenerate tumors locally and/or
at distant sites. Here, we propose a putative explanation for cisplatin
resistance using the CSC hypothesis as mechanistic underpinning.
Indeed, we observed that cisplatin enhances the fraction of head and
neck CSCs (ALDHhighCD44high cells), which are known to be highly
tumorigenic [16]. We also observed that IL-6 further enhances the
stemness of HNSCC cells resistant to cisplatin, as demonstrated by
higher levels of Bmi-1 and CD44 expression when IL-6 and cisplatin
are combined. These findings provide preclinical support for a combi-
nation therapy that includes cisplatin and a targeted drug (e.g., IL-6R
inhibitor) that inhibits important CSC functions in patients with head
and neck cancer.
Figure 4. Cisplatin-resistant cells display cancer stemlike features. Cisplatin-resistant cells were generated by subculturing these cells in
presence of increasing concentrations of cisplatin from 0.5 to 12 μM during a 3-month period. (A) Photomicrographs of parental cells
(UM-SCC-22B) and cells resistant to 1 μM cisplatin (UM-SCC-22BCis1), 6 μM cisplatin (UM-SCC-22BCis6), or 12 μM cisplatin (UM-SCC-
22BCis12). (B) Graph depicts number of orospheres generated with parental UM-SCC-22B cells or cisplatin-resistant cells (UM-SCC-
22BCis12) treated with cisplatin (0 or 2 μM) and/or rhIL-6 (0 or 20 ng/ml) for 10 days in ultralow attachment plates. Different lowercase
letters depict P < .05. (C) Western blot analysis of the expression of Bmi-1 in cisplatin-resistant cells (UM-SCC-22BCis1, UM-SCC-
22BCis4, UM-SCC-22BCis6, and UM-SCC-22BCis12), compared to parental cells (UM-SCC-22B). (D and E) Western blot analysis of
the expression of Bmi-1 (D) or Oct-4 (E) in cisplatin-resistant cells (UM-SCC-22BCis1 and UM-SCC-22BCis12), compared to parental cells
(UM-SCC-22B). Cells were treated with cisplatin (0-2 μM) and/or rhIL-6 (0-20 ng/ml) for 24 hours.
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CSCs are resilient cells that play a major role in resistance to
chemotherapy and radiotherapy in several tumor types [41–43].
For example, a relatively quiescent subpopulation of glioma cells
with CSC properties was implicated in tumor regrowth after
treatment of glioblastomas with temozolomide [13]. Furthermore,
long-term trastuzumab treatment enriches the CSC population in
breast cancer [11]. We observed here that cisplatin enhanced the
fraction of head and neck CSCs in vivo, despite the lack of a sig-
nificant change in the overall tumor volume with the dosing used
here. In search for a mechanism for this response, we performed a
series of in vitro studies that revealed the following: 1) A 24-hour
exposure to 2 μM cisplatin does not mediate a decrease in the sur-
vival of unsorted HNSCC cells, when compared to untreated con-
trols. However, we observed that a 24-hour exposure to 2 μM
cisplatin doubled the fraction of ALDH+CD44+ cells. Notably, we
evaluated 10,000 events for all the experimental conditions in the
flow cytometry experiments. Therefore, cisplatin was able to in-
crease the fraction of CSCs despite the fact that the total number
of cells remained unchanged. 2) We observed a significant increase
in the number of orospheres on treatment of parental HNSCC cells
with 2 μM cisplatin. These data support the notion that cisplatin
enhances the ALDH+CD44+ fraction because only these cells
survive/proliferate under low attachment conditions. And 3) even
very low concentrations of cisplatin (subapoptotic) were capable of
inducing expression of the self-renewal of Bmi-1 and stem cell
marker CD44 in unsorted HNSCC cells. Collectively, these data
suggest that cisplatin was able to transform cells to be more ALDH+
and CD44+. Importantly, these data indicate that ALDHhighCD44high
cells are resistant to cisplatin therapy. Considering the highly tumori-
genic nature of these cells [16], this finding might explain, at least
in part, the frequent occurrence of tumor relapse and distant me-
tastases observed in patients with head and neck cancer treated
with cisplatin.
It is well established that IL-6 signaling through the STAT3
pathway is employed by tumor cells to circumvent apoptosis and
maintain proliferation and neoplastic growth [34,44]. Thus, it has
been postulated that IL-6 participates in resistance to chemothera-
peutic drugs [45,46]. It has been shown that the expansion of the
CSC population observed in trastuzumab-treated mammary tu-
mors is mediated by IL-6 signaling [11]. In head and neck cancer,
cisplatin induces expression of IL-6, which mediates a transient
increase in the tumorigenic potential of cancer cells [47]. Further-
more, sensitivity to chemotherapy appears to be modulated by
lethal-7 (Let-7) through the regulation of IL-6/STAT3 pathway
in head and neck cancer [48]. Notably, high serum IL-6 level is
a strong predictor of the poor survival of patients with head and neck
cancer [25]. We have recently observed that CSCs reside in perivascular
niches in head and neck cancer [16] and that tumor-associated endo-
thelial cells express high levels of IL-6, whereas ALDHhighCD44high
cells express higher levels of IL-6R than ALDHlowCD44low cells
(unpublished observations). Here, we observed that IL-6 contributes
to cisplatin-induced stemness (Bmi-1 and CD44 expression and
number of orospheres) of head and neck cancer cells and that thera-
peutic blockade of IL-6R signaling with a humanized monoclonal
antibody partially inhibits cisplatin-induced Bmi-1 expression. Inter-
estingly, the blockade of the receptor IL-6R was more effective than
blockade of the ligand IL-6 in inhibiting Bmi-1 expression in re-
sponse to cisplatin. These data suggest that an autocrine loop perhaps
mediated in part by another IL-6R ligand (i.e., ciliary neurotrophic
factor) contributes to the effect of cisplatin on HNSCC self-renewal.
Notably, even cells pretreated with cisplatin for a long period of
time (e.g., UM-SCC-22BCis12) still showed higher expression of
Figure 5. IL-6 activates STAT3 signaling and induces Bmi-1 expression in cisplatin-resistant cells. (A) Western blot analyses for
phosphorylated and total STAT3 and ERK in cisplatin-resistant cells (UM-SCC-22BCis1, UM-SCC-22BCis4, UM-SCC-22BCis6, and UM-SCC-
22BCis12), compared to parental cells (UM-SCC-22B). (B) Western blot analyses for expression of IL-6R in cisplatin-resistant cells (UM-SCC-
22BCis series), compared to parental cells (UM-SCC-22B). Cells were treated with cisplatin (0-2 μM) and/or rhIL-6 (0 or 20 ng/ml) for 24 hours.
(C) Western blot analysis of Bmi-1 in cisplatin-resistant cells (UM-SCC-22BCis1), compared to parental cells. Cells were treated with cisplatin
(0-2 μM) and/or rhIL-6 (0 or 20 ng/ml) in presence of anti–IL-6 or anti–IL-6R antibody for 24 hours.
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Bmi-1 on exposure to IL-6, suggesting that the effect of cisplatin per-
sists over time.
Collectively, these data demonstrate that cisplatin enhances the frac-
tion of putative head and neck CSCs (defined as ALDHhighCD44high
cells), which are known to be highly tumorigenic in preclinical
models of HNSCC [16]. We have also observed that IL-6 contrib-
utes to cisplatin-induced stemness, suggesting that a combination
therapy involving a platinum-based drug and an IL-6R inhibitor
might be beneficial for patients with HNSCC.
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Figure W1. Cisplatin enhances the fraction of CSCs in HNSCC. Graphs depict the viability of UM-SCC-22B and UM-SCC-1 cells, as
determined by the SRB assay. Cells were treated with cisplatin (0-20 μM) for 48 to 96 hours. The IC50 was determined at 72 hours.
Figure W2. The table depicts the demographic and stage information of the patients fromwhomwe obtained the primary human HNSCC
specimens that were used here. These tumors were dissociated by mechanic and enzymatic digestion, and nonviable and lineage cells
were excluded. The total number and the percentage of ALDHhighCD44high and ALDHlowCD44low cells sorted are depicted.
Figure W3. Western blot analysis depicts the expression of CD44
and Bmi-1 in UM-SCC-1 cells treated with (A) rhIL-6 (0 or 20 ng/ml)
or (B) cisplatin (0-5 μM) for 24 hours.
